GSK plc (LON:GSK - Get Free Report) insider Emma Walmsley acquired 9 shares of the company's stock in a transaction on Tuesday, September 9th. The stock was acquired at an average price of GBX 1,486 per share, for a total transaction of £133.74.
Emma Walmsley also recently made the following trade(s):
- On Monday, August 11th, Emma Walmsley bought 9 shares of GSK stock. The stock was purchased at an average price of GBX 1,408 per share, with a total value of £126.72.
GSK Price Performance
Shares of GSK traded down GBX 24.50 during trading hours on Monday, reaching GBX 1,479. The company had a trading volume of 13,732,532 shares, compared to its average volume of 12,314,056. The firm has a 50 day simple moving average of GBX 1,428.95 and a 200-day simple moving average of GBX 1,432.29. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The company has a market capitalization of £59.57 billion, a price-to-earnings ratio of 1,788.39, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a 12-month low of GBX 1,242.50 and a 12-month high of GBX 1,649.25.
GSK (LON:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported GBX 75.30 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Research analysts expect that GSK plc will post 175.980975 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the stock. Shore Capital reissued a "buy" rating and issued a GBX 2,100 price objective on shares of GSK in a research note on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a GBX 1,450 price objective on shares of GSK in a research note on Thursday, July 31st. JPMorgan Chase & Co. decreased their price objective on GSK from GBX 1,460 to GBX 1,400 and set an "underweight" rating on the stock in a research note on Monday, August 4th. Finally, Berenberg Bank reaffirmed a "hold" rating and set a GBX 1,600 price target on shares of GSK in a research note on Friday, July 18th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, GSK currently has a consensus rating of "Hold" and a consensus target price of GBX 1,637.50.
View Our Latest Stock Analysis on GSK
GSK Company Profile
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Recommended Stories
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
